Danaher to acquire Aldevron in deal valued at $9.6B

By Will Morton, The Science Advisory Board contributing writer

Danaher announced it has signed a deal to buy DNA and messenger RNA (mRNA) manufacturer Aldevron for approximately $9.6 billion. Aldevron will operate as a standalone company in Danaher's Life Sciences business segment and is expected to boost Danaher's activities in genomic medicine.

Aldevron manufactures plasmid DNA, mRNA, and proteins, and serves biotechnology and pharmaceutical customers involved in research, clinical, and commercial applications. The privately held company is based in Fargo, ND, and employs approximately 600 people.

Rainer Blair, Danaher president and CEO, said the deal is expected to boost Danaher's activities in genomic medicine and improve the company's ability to support customers developing vaccines and other therapies, such as in cell and gene therapy.

Danaher said it expects to finance the purchase using cash on hand and proceeds from the issuance of commercial paper.

In 2020, Danaher bought GE's biopharma business.

The Aldevron purchase is subject to customary conditions, including receipt of applicable regulatory approvals, according to the company. Danaher operates more than 20 companies and a team of about 69,000 associates worldwide.


Copyright © 2021 scienceboard.net
 

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?